Boston Scientific (NYSE:BSX - Get Free Report) was upgraded by Leerink Partnrs to a "strong-buy" rating in a research note issued on Monday,Zacks.com reports. Leerink Partnrs also issued estimates for Boston Scientific's Q2 2025 earnings at $0.73 EPS, Q3 2025 earnings at $0.72 EPS, Q4 2025 earnings at $0.73 EPS, Q1 2026 earnings at $0.79 EPS, Q2 2026 earnings at $0.82 EPS, Q3 2026 earnings at $0.84 EPS, Q4 2026 earnings at $0.90 EPS, FY2026 earnings at $3.36 EPS and FY2027 earnings at $3.88 EPS.
BSX has been the subject of a number of other research reports. Needham & Company LLC restated a "buy" rating and issued a $115.00 price objective on shares of Boston Scientific in a research note on Wednesday, May 28th. Robert W. Baird upped their price target on Boston Scientific from $115.00 to $120.00 and gave the company an "outperform" rating in a research report on Thursday, April 24th. Royal Bank of Canada boosted their target price on Boston Scientific from $116.00 to $120.00 and gave the stock an "outperform" rating in a research report on Thursday, April 24th. Leerink Partners initiated coverage on shares of Boston Scientific in a report on Monday. They set an "outperform" rating and a $118.00 price objective for the company. Finally, Argus set a $130.00 price target on shares of Boston Scientific in a research report on Tuesday, February 18th. Twenty-two equities research analysts have rated the stock with a buy rating and three have given a strong buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $116.09.
Get Our Latest Research Report on BSX
Boston Scientific Stock Performance
BSX opened at $101.49 on Monday. Boston Scientific has a 1 year low of $71.88 and a 1 year high of $107.17. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.08 and a quick ratio of 1.02. The company has a market capitalization of $150.15 billion, a PE ratio of 81.19, a price-to-earnings-growth ratio of 2.79 and a beta of 0.68. The business has a fifty day simple moving average of $101.25 and a 200 day simple moving average of $98.87.
Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings data on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.67 by $0.08. The business had revenue of $4.66 billion during the quarter, compared to analyst estimates of $4.57 billion. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. The firm's quarterly revenue was up 20.9% on a year-over-year basis. During the same quarter last year, the business earned $0.56 EPS. Research analysts expect that Boston Scientific will post 2.85 EPS for the current year.
Insider Buying and Selling
In related news, EVP Joseph Michael Fitzgerald sold 56,372 shares of the stock in a transaction that occurred on Wednesday, June 4th. The stock was sold at an average price of $102.88, for a total value of $5,799,551.36. Following the completion of the transaction, the executive vice president now directly owns 178,342 shares in the company, valued at approximately $18,347,824.96. This represents a 24.02% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Vance R. Brown sold 4,826 shares of the business's stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $95.09, for a total transaction of $458,904.34. Following the completion of the sale, the senior vice president now directly owns 36,193 shares in the company, valued at $3,441,592.37. This trade represents a 11.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 411,970 shares of company stock worth $42,406,693 in the last 90 days. Insiders own 0.50% of the company's stock.
Institutional Investors Weigh In On Boston Scientific
Institutional investors and hedge funds have recently modified their holdings of the company. 1248 Management LLC acquired a new position in Boston Scientific in the first quarter valued at approximately $35,000. Modern Wealth Management LLC raised its stake in Boston Scientific by 7.9% during the 1st quarter. Modern Wealth Management LLC now owns 2,974 shares of the medical equipment provider's stock valued at $300,000 after acquiring an additional 218 shares during the last quarter. Birmingham Capital Management Co. Inc. AL purchased a new position in shares of Boston Scientific in the 1st quarter valued at approximately $202,000. Strs Ohio acquired a new stake in shares of Boston Scientific during the first quarter worth $110,830,000. Finally, Advisors Capital Management LLC lifted its stake in shares of Boston Scientific by 27.5% in the 1st quarter. Advisors Capital Management LLC now owns 4,400 shares of the medical equipment provider's stock worth $444,000 after acquiring an additional 948 shares during the period. Hedge funds and other institutional investors own 89.07% of the company's stock.
About Boston Scientific
(
Get Free Report)
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Boston Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Boston Scientific wasn't on the list.
While Boston Scientific currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
